MedTrace Logo

Trichomonas Vaginalis Recurrence Among HIV+ Women

NCT01018095 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 270

Last updated 2016-12-20

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine if the 2 gram single dose of metronidazole is as effective as the 7 day 500 mg BID dose for treatment of Trichomonas vaginalis (TV) among HIV-infected women.

Conditions

  • Trichomonas Infections
  • HIV Infections

Interventions

DRUG

Metronidazole

2 gm single dose versus 7 day 500 mg BID dose

Sponsors & Collaborators

  • National Institute of Allergy and Infectious Diseases (NIAID)

    collaborator NIH

  • Tulane University Health Sciences Center

    lead OTHER

Principal Investigators

  • Patricia Kissinger, Ph.D. · Tulane University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-05-31
Primary Completion
2009-07-31
Completion
2009-08-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01018095 on ClinicalTrials.gov